Market Place
Sourcing Support
Ferring Presents REBYOTA® Data Analyses at ACG 2024
28 Oct 2024 //
BUSINESSWIRE
Ferring Pharmaceuticals Commits To Advancing Fertility Care At ASRM
18 Oct 2024 //
BUSINESSWIRE
Ferring Presents Rebyota Outcomes Data At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
Ferring cuts ribbon at new gene therapy manufacturing hub
04 Oct 2024 //
FIERCE PHARMA
Ferring`s Treat-To-Target Approach In Colitis found effective
30 Sep 2024 //
BUSINESSWIRE
Ferring Presents SI-6603 Phase 3 Data At NASS 2024
25 Sep 2024 //
BUSINESSWIRE
Ferring To Present SI-6603 Data For Disc Herniation At NASS 2024
09 Sep 2024 //
BUSINESSWIRE
Ferring Presents SI-6603 Phase 3 Data For Lumbar Disc Herniation At ASPN
15 Jul 2024 //
BUSINESSWIRE
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, for Herniation
24 Jun 2024 //
BUSINESSWIRE
FerriFerring launches online tool, educational platform around male fertiling
20 Jun 2024 //
FIERCE PHARMA
First Real-World REBYOTA Data Presented At DDW 2024
20 May 2024 //
BUSINESSWIRE
ADSTILADRIN® demonstrates durable bladder preservation and safety in Phase 3.
06 May 2024 //
BUSINESSWIRE
Ferring, SK Pharmteco Partner For Commercial Gene Therapy Manufacturing
18 Apr 2024 //
BUSINESSWIRE
With SK partnership, Ferring boosts long-term Adstiladrin supply
18 Apr 2024 //
FIERCE PHARMA
Ferring Adds 3 NMIBC Trials With ADSTILADRIN®
16 Apr 2024 //
BUSINESSWIRE
Ferring Presents Ph 3 Data for Investigational Treatment at ASIPP 2024
08 Apr 2024 //
BUSINESSWIRE
Ferring`s Bio-tropin (Somatropin ) Receives Suppl Approvals in the U.S
02 Apr 2024 //
FDA
Ferring`s Zomacton (Somatropin) Receives Suppl Approvals in the U.S
02 Apr 2024 //
FDA
Phase 4 Study Evaluating Use of ADSTILADRIN in Real-World Setting
24 Jan 2024 //
BUSINESSWIRE
Ferring Announces Full Availability of ADSTILADRIN in the U.S.
16 Jan 2024 //
BUSINESSWIRE
Ferring lays off 134 staffers in the US
12 Dec 2023 //
FIERCE PHARMA
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration
11 Dec 2023 //
BUSINESSWIRE
Ferring Pharmaceuticals lays off 134 employees between NJ and MN locations
11 Dec 2023 //
ENDPTS
New Data Show Durable Response Following Treatment with ADSTILADRIN
29 Nov 2023 //
BUSINESSWIRE
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA
03 Oct 2023 //
BUSINESSWIRE
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA
21 Sep 2023 //
BUSINESSWIRE
Ferring cautiously rolls out bladder cancer gene therapy
13 Sep 2023 //
FIERCE PHARMA
Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy
25 Aug 2023 //
BIOSPACE
Largest Safety Analysis From Five Prospective Trials for REBYOTA Published
11 Jul 2023 //
BUSINESSWIRE
Enforcement Report - Week of July 5, 2023
05 Jul 2023 //
FDA
Ferring appoints new Executive Chairman among key changes to Board of Directors
22 Jun 2023 //
BUSINESSWIRE
Ferring successfully increases its second Swiss Franc Bond offering by CHF 80 M
16 Jun 2023 //
BUSINESSWIRE
Ferring looks to scale up gene therapy; EuroAPI to boost production of pain medicine
15 Jun 2023 //
ENDPTS
Ferring Pharmaceuticals Receives U.S. FDA Approval for Gene Therapy ADSTILADRIN
13 Jun 2023 //
BUSINESSWIRE
Health Canada Issues Recall of Ferring`s Endometrin effervescent vaginal tablets
02 Jun 2023 //
HEALTH CANADA
Ferring Announces Positive Topline Phase 3 Results for SI-6603
26 May 2023 //
BUSINESSWIRE
Four Analyses of Data for REBYOTA™ the First FDA-Approved Microbiome
08 May 2023 //
BUSINESSWIRE
CORONA, Ferring partner to commercialise maternal health, urology products India
04 May 2023 //
EXPRESS PHARMA
Ferring & BioInnovation enter new strategic collaboration women’s health
18 Apr 2023 //
BUSINESSWIRE
Ferring to Present Analyses of Data for REBYOTA™ the First FDA-Approved
18 Apr 2023 //
BUSINESSWIRE
Ferring`s research site closure signals shift from internal R&D
11 Apr 2023 //
FIERCE BIOTECH
Ferring shuts down U.S. research institute, cutting 89 staffers
29 Mar 2023 //
FIERCE BIOTECH
Ferring Announces Abstract of the Study of Rekovelle
13 Mar 2023 //
BUSINESSWIRE
Ferring Announces Availability of REBYOTA – the First Microbiome-Based Treatment
14 Feb 2023 //
BUSINESSWIRE
U.S. FDA Approves Ferring Pharma`s First Gene Therapy For Bladder Cancer
17 Dec 2022 //
PRESS RELEASE
FDA Approves First Fecal Microbiota Product Rebyota
01 Dec 2022 //
FDA
Pivotal Phase 3 Efficacy & Safety Data for Ferring’s RBX2660 Published in Drugs
07 Nov 2022 //
BUSINESSWIRE
Ferring halts shipments of fertility med Menopur
28 Oct 2022 //
FIERCEPHARMA
Ferring Presents Seven New Analyses at ACG 2022 for RBX2660
24 Oct 2022 //
BUSINESSWIRE
Ferring Pharmaceuticals Announces the Launch of FertilityWise
21 Oct 2022 //
PRNEWSWIRE
Ferring Presents Analyses of Quality of Life & Efficacy Data for RBX2660
20 Oct 2022 //
BUSINESSWIRE
Ferring to Present Data Highlighting Future Assisted Reproductive Technology
19 Oct 2022 //
PRNEWSWIRE
Ferring & Blackstone Life Sciences restructure novel gene therapy collaboration
18 Oct 2022 //
PRESS RELEASE
Ferring to Present Analyses for RBX2660 in Patients at ACG 2022
11 Oct 2022 //
BUSINESSWIRE
Ferring to Present Analyses for Microbiota-Based Biotherapeutic RBX2660
06 Oct 2022 //
BUSINESSWIRE
FDA committee votes for Ferring`s C. difficile therapy
23 Sep 2022 //
FIERCEBIOTECH
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
22 Sep 2022 //
BUSINESSWIRE
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660
09 Aug 2022 //
BUSINESSWIRE
FDA`s vaccine adcomm to review 1st fecal transplant for C. difficile infections
08 Aug 2022 //
ENDPTS
